Experimental triple therapy targets tough childhood liver cancer
NCT ID NCT07188311
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing a combination of three drugs—pucotenlimab (an immunotherapy), lenvatinib (a targeted therapy), and irinotecan (chemotherapy)—in children aged 2-18 with advanced or relapsed/refractory hepatoblastoma, a rare liver cancer. The goal is to see if this combination can control the disease or slow its progression. The trial plans to enroll 24 participants who have already tried at least one prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pucotenlimab (an immunotherapy drug) combined with lenvatinib (a targeted therapy) and irinotecan (chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for children with hard-to-treat liver cancer that has not responded to standard therapy.
What could go wrong
This is a small, early-phase study with only 24 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yizhuo Zhang
RECRUITINGGuangdong, Guangzhou, 510060, China